roflumilast
arcutis,astrazeneca
['derm', 'roflumilast', 'arcutis']
new data from arcutis stratum pivotal phase 3 trial of roflumilast foam 0.3% in seborrheic dermatitis presented at european academy of dermatology and venereology (eadv) congress - met its primary endpoint with 80% of individuals treated with roflumila... 
CEO Of Digital Media Online